PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Negative R&D growth (spending reduction) needs careful analysis. Benjamin Graham would examine impact on competitive position.
28.86%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
-40.21%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
6.04%
Operating expenses growth 5-10% suggests significant expansion. Howard Marks would investigate necessity.
6.04%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
-100.00%
Negative interest expense growth needs verification. Benjamin Graham would examine debt reduction strategy.
-40.21%
Negative D&A growth needs verification. Benjamin Graham would examine asset reduction strategy.
-66.22%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-6.04%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-333.64%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-65.74%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative tax expense growth needs verification. Benjamin Graham would examine sustainability.
-65.74%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-47.67%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-53.82%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
12.14%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
7.50%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.